Ruby Bio

Cover Block

Name	Ruby Bio
Tagline	Yeast-based biomanufacturing of sustainable biosurfactants and ingredients
Headquarters	San Carlos, CA, USA
Founded	2022
Stage	Seed
Business Model	B2B
Industry	Cleantech / Climatetech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	$10M+ (total disclosed ~$13.1M)

Links

• Website: https://www.rubybio.com
• LinkedIn: https://www.linkedin.com/company/ruby-bio

What an Investor Needs First

Ruby Bio is an early-stage biomanufacturing company developing sustainable biosurfactants and ingredients through a yeast-based platform. Founded in 2022 by Charlie Silver and Pavan Kambam, the company uses naturally occurring yeast to convert sugars into biodegradable, non-toxic molecules that can serve as alternatives to petroleum or palm-derived inputs in personal care, food, and industrial applications [Startup Intros, 2024]. The core differentiation rests on a proprietary biosynthesis process, which the company has reportedly scaled from a 10-liter to a 5,000-liter bioreactor at a Department of Energy facility [Saurabh Malani LinkedIn, 2026]. The founding team brings relevant scaling experience from prior biotech ventures, with the CEO having scaled Mission Bio and the CTO having worked on biosynthesis at Greenlight Biosciences and Clara Foods [Startup Intros, 2024].

To date, the company has raised at least $13.1 million across three rounds, with backing from a syndicate of nine investors including Alumni Ventures and Earth VC [CBInsights, 2024] [Tracxn, May 2025]. The business model is B2B, targeting manufacturers seeking sustainable ingredients. Over the next 12-18 months, the critical watchpoints will be the transition from pilot-scale production to commercial partnerships, the announcement of initial offtake agreements, and any further capital raises to fund the significant scale-up required in biomanufacturing. Data Accuracy: YELLOW -- Core claims rely on company website and founder profiles; funding data is aggregated from multiple platforms.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Cleantech / Climatetech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	$10M+ (total disclosed ~$13,100,000)

Inside the Company

Ruby Bio was incorporated in 2022, establishing its headquarters and pilot facility in San Carlos, California [Crunchbase, 2024]. The company's founding narrative centers on applying scalable biomanufacturing to sustainable chemistry.

Key operational milestones include a seed round in September 2023 [Crunchbase, Sep 2023]. A significant technical development occurred in 2026, when the company reported successfully scaling its biosurfactant production from a 10-liter to a 5,000-liter bioreactor at the Advanced Biofuels and Bioproducts Process Development Unit (ABPDU), a facility operated by Lawrence Berkeley National Laboratory [Saurabh Malani LinkedIn, 2026]. Data Accuracy: YELLOW -- Company founding and location corroborated by Crunchbase; the 2023 seed round is listed but details are incomplete. The 2026 scale-up milestone is cited from a LinkedIn post by an individual affiliated with the ABPDU program.

Under the Hood

Ruby Bio's core proposition is a biomanufacturing platform that uses yeast as the production engine for specialty chemicals. Its proprietary yeast strains convert low-cost sugars into high-value, biodegradable molecules like biosurfactants, food emulsifiers, and polymer building blocks [Startup Intros, 2024].

The technology's most concrete public milestone is a scale-up demonstration conducted at a government facility. The company successfully scaled its naturally-derived biosurfactants from a 10-liter volume to a 5,000-liter fermentation run at the Advanced Biofuels and Bioproducts Process Development Unit (ABPDU) [Saurabh Malani LinkedIn, 2026]. The company operates a pilot facility in San Carlos, California [Startup Intros, 2024]. Data Accuracy: YELLOW -- Product claims are sourced from company materials and a third-party profile; the scale-up milestone is corroborated by a LinkedIn post referencing a government lab case study.

Market Research

The push for sustainable supply chains is creating a tangible market for bio-based chemicals. The company cites a biosurfactants market valued at over $50 billion [Saurabh Malani LinkedIn, 2026]. Third-party analysis from Grand View Research estimated the global biosurfactants market at $5.8 billion in 2023, projecting a compound annual growth rate of 11.6% through 2030 [Grand View Research, 2023]. The company's target SAM spans personal care, home care, food & beverage, and industrial polymers [Startup Intros, 2024].

Metric	Value
Biosurfactants Market (2023)	5.8 $B
Projected CAGR (2023-2030)	11.6 %

Data Accuracy: YELLOW -- Market size figure is company-cited without a primary source; growth rate is from an analogous third-party report.

Competition and Substitutes

Ruby Bio enters a market where competition is defined by the choice of feedstock and the scale of bioprocess engineering.

Company	Positioning	Stage / Funding	Notable Differentiator
Ruby Bio	Yeast-based biomanufacturing of biosurfactants, emulsifiers, and polymer blocks from sugars.	Seed; $13.1M total disclosed [CBInsights, 2024][Tracxn, May 2025]	Founder pedigree in scaling biotech; pilot scale at 5,000 L demonstrated [Saurabh Malani LinkedIn, 2026].
Holiferm	Microbial fermentation for biosurfactants using sustainable feedstocks.	Venture-backed; raised £21M Series B in 2023 [Holiferm, 2023].	Commercial-scale production in the UK; partnerships with major CPG companies.
Locus Fermentation Solutions	Fermentation-derived ingredients for agriculture, industrial, and consumer markets.	Later-stage; raised $117M prior to 2022 [Locus FS, 2022].	Broad product portfolio across multiple verticals.

Data Accuracy: YELLOW -- Competitor funding and positioning are from public announcements, but Ruby Bio's commercial progress is inferred from limited primary source updates.

Opportunity

The headline opportunity for Ruby Bio is to become a primary biomanufacturing platform for high-performance, yeast-derived ingredients. The company's foundational bet is on a proven biological chassis, naturally occurring yeast. The evidence of scaling its process from 10 liters to 5,000 liters at the Advanced Biofuels and Bioproducts Process Development Unit demonstrates a critical technical de-risking step [Saurabh Malani LinkedIn, 2026].

Scenario	What happens	Catalyst	Why it's plausible
Ingredient Supplier to CPG Giants	Ruby Bio becomes a contracted supplier of biosurfactants or emulsifiers for a major personal care or food & beverage company.	A multi-year offtake agreement with a Fortune 500 consumer packaged goods firm.	The team includes food science leadership from PepsiCo and Tyson Foods [Startup Intros, 2024].
Platform Licensing for Niche Polymers	The yeast strain and bioprocess are licensed to chemical companies for producing specific, high-margin polymer building blocks.	A joint development agreement with a specialty chemical manufacturer.	The company's published technology scope includes "polymer building blocks" [Startup Intros, 2024].

Data Accuracy: YELLOW -- Market size and technical scaling claims are from a single LinkedIn post by an industry figure; team background claims are from one aggregated profile source.

Sources

1. [Startup Intros, 2024] Ruby Bio: Funding, Team & Investors | https://startupintros.com/orgs/ruby-bio
2. [CBInsights, 2024] Ruby Bio - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/ruby-bio
3. [Crunchbase, 2024] Ruby Bio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/ruby-bio
4. [Crunchbase, Sep 2023] Seed Round - Ruby Bio - 2023-09-26 | https://www.crunchbase.com/funding_round/ruby-bio-seed--e2dc365f
5. [Tracxn, May 2025] Ruby Bio - 2026 Funding Rounds & List of Investors - Tracxn | https://tracxn.com/d/companies/rubybio/__n6URmV9NGj96Ef-ogT1Da5Z6qpZf7SahCm6SCbCurts/funding-and-investors
6. [Saurabh Malani LinkedIn, 2026] Saurabh Malani, PhD - San Francisco, California, United States | Professional Profile | LinkedIn | https://www.linkedin.com/in/saurabh-malani/
7. [Grand View Research, 2023] Biosurfactants Market Size, Share & Trends Analysis Report, 2023 - 2030 | https://www.grandviewresearch.com/industry-analysis/biosurfactants-market-report
8. [Holiferm, 2023] Holiferm raises £21 million to scale production of sustainable biosurfactants | https://holiferm.com/news/holiferm-raises-21-million-to-scale-production-of-sustainable-biosurfactants/
9. [Locus FS, 2022] Locus Fermentation Solutions | https://www.locusfs.com/